Autosomal dominant adult-onset demyelinating leukodystrophy (ADLD; OMIM \#169500) is a slowly progressive adult-onset leukoencephalopathy that predominantly affects the cerebral white matter. The onset of ADLD is typically in the fourth and fifth decade of life.^[@R1]^ Patients with ADLD are clinically characterized by early development of autonomic symptoms such as bladder and/or bowel impairment and orthostatic hypotension. Autonomic symptoms usually precede or occur together with other accompanying clinical features such as pyramidal signs and cerebellar ataxia. Cognitive impairment is observed in some patients.^[@R2],[@R3]^ Characteristic MR images include diffuse and symmetrical lesions in the cerebral white matter and cerebellar peduncles. The periventricular rim adjacent to the lateral ventricle in the cerebral white matter is spared or less affected.^[@R1]^

Duplication of lamin B1 (*LMNB1*) encoding lamin B1 has been identified as a cause of ADLD.^[@R4]^ To date, 26 pedigrees with ADLD carrying *LMNB1* duplication have been reported from different ethnic backgrounds.^[@R3],[@R5],[@R6]^ The regions of duplication commonly include the entire *LMNB1*, but differed in size among the pedigrees, ranging from 128 to 475 kb.^[@R7]^ In 2015, it was reported that a deletion of 660 kb in the region upstream of *LMNB1* was identified as the cause of ADLD in an Italian pedigree.^[@R8]^ In both mutations, i.e., duplication and deletion upstream of *LMNB1*, the expression mRNA level of *LMNB1* was elevated.^[@R4],[@R7],[@R8]^ The key mechanism involved in the ADLD pathogenesis seems to be lamin B1 overproduction; however, it has not been fully understood how lamin B1 overproduction causes demyelination, leading to ADLD.

In this study, we analyzed the copy number variation (CNV) of *LMNB1* and the upstream genes to identify *LMNB1*-related ADLD in families with adult-onset leukoencephalopathies of unknown etiology. By this analysis, we identified 4 ADLD pedigrees including 3 families with *LMNB1* duplication and 1 family with the upstream deletion of *LMNB1*. We here report the genetic and clinical characteristics of Japanese families with *LMNB1*-related ADLD.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

This study was conducted in accordance with the Helsinki declaration and approved by the Institutional Review Board of Niigata University. Written informed consent was obtained from the patients or their caregivers.

Patients {#s1-2}
--------

One-hundred ten patients clinically suspected of having an adult-onset leukoencephalopathy, whose etiologies have not been determined, were referred to our institute for genetic analysis between September 2015 and April 2017. Genetic analysis was performed by PCR-based Sanger sequencing analysis of genes including colony-stimulating factor 1 receptor (*CSF1R*), *AARS2*, *NOTCH3*, and *SNORD118*. By this analysis, 11 patients who were found to harbor *CSF1R* mutations, 2 patients with *AARS2* mutations, 2 patients with *NOTCH3* mutations, 1 patient with *SNORD118* mutations, and 1 patient with neuronal intranuclear inclusion disease were excluded. The remaining 93 patients were included in this study.

Genetic analysis {#s1-3}
----------------

Genomic DNA was extracted from peripheral leukocytes using a QIAamp DNA Blood Maxi kit (QIAGEN, Hilden, Germany). CNV was analyzed by real-time PCR assay using TaqMan probes (Thermo Fischer Scientific, Waltham, MA) designed for exons 3 (Hs02537023_cn), 6 (Hs00696436_cn), and 10 (Hs00579415_cn) of *LMNB1.* TaqMan probes were also designed for exon 5 of phosphorylated adaptor for RNA export (*PHAX*) (Hs0092512_cn), exon 8 of aldehyde dehydrogenase 7 family member A1 (*ALDH7A1*) (Hs00222439_cn), and exon 2 of GRAM domain containing 3 (*GRAMD3*) (Hs01106540_cn) to examine the CNV of the upstream genomic region of *LMNB1*. The amount of a PCR product was calculated on the basis of the threshold cycle (C~t~), namely, the cycle in which fluorescence was detected above the baseline on an ABI PRISM 7900HT instrument (Applied Biosystems, Waltham, MA). We analyzed the results using CopyCaller Software v2.0 (Applied Biosystems). The control DNA CEPH 1347-02 was used as a reference genomic DNA sample, and the endogenous control was calculated by TaqMan copy number reference assay. The range of genomic CNVs around *LMNB1* was examined by microarray-based copy number profiling using an Affymetrix CytoScan HD array (Thermo Fischer Scientific).

*LMNB1* expression assay {#s1-4}
------------------------

Total RNA was extracted from patients with *LMNB1*-related ADLD using a PAXgene blood RNA kit (QIAGEN). RNA integrity number (RIN) was determined using Bioanalyzer 2100. Complementary DNA was synthesized by SuperScript IV VILO Master Mix (Thermo Fischer Scientific) using RNA showing a RIN score of 7 or higher. mRNA expression level was analyzed by real-time PCR assay using 2 TaqMan probes (Hs01059207_m1, Hs01059210_m1) (Thermo Fischer Scientific) designed for *LMNB1*. The expression of *LMNB1* was normalized to that of *ACTB* (Hs99999903_m1) or *TBP* (Hs99999910_m1). The amount of the PCR product was calculated on the basis of C~t~, the cycle where fluorescence was detected above the baseline on an ABI PRISM 7900HT instrument (Applied Biosystems). We analyzed the result by a comparative C~t~ method, in which the average of 7 control subjects (age, 53.1 ± 17.8 years, mean ± SD) was set to 1. Data are presented as median ± SD. Statistical analysis was performed with the Mann--Whitney *U* test.

Clinical assessment {#s1-5}
-------------------

We retrospectively analyzed the clinical characteristics of 6 patients from 4 families with *LMNB1*-related ADLD. We examined their sex, ages at onset and examination, initial symptoms, and the presence or absence of clinical symptoms including autonomic nervous dysfunction, pyramidal tract signs, and cerebellar ataxia using medical records. Cognitive functions were evaluated by Mini-Mental State Examination or Montreal Cognitive Assessment. Brain MRI with T1-weighted imaging (T1WI), T2-weighted imaging, fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) was performed on the 6 patients with ADLD.

Results {#s2}
=======

*LMNB1* duplication {#s2-1}
-------------------

We examined the CNV of *LMNB1* in 93 patients with adult-onset leukoencephalopathy of unknown etiology by TaqMan-based real-time PCR assay. The gene dosage of *LMNB1* was increased approximately by 1.5-fold in 4 patients from 3 families (pedigrees I--III, [figure 1A](#F1){ref-type="fig"}). This suggests that these patients were heterozygous for *LMNB1* duplication.

![Analysis of CNVs of *LMNB1* and its upstream region\
(A) Gene dosages for exons 3, 6, and 10 of *LMNB1* were determined by TaqMan-based real-time PCR assay. The copy numbers of 3 exons of *LMNB1* in patients 1--4 were increased by approximately 1.5-fold compared with control subjects, suggesting the presence of duplication of *LMNB1* in these patients. (B) The copy number variations of regions upstream of *LMNB1* including *GRAMD3*, *ALDH7A1*, and *PHAX* were determined by TaqMan-based real-time PCR assay. The copy numbers of *ALDH7A1* and *PHAX* were decreased approximately by half in patients 5 and 6, suggesting the presence of the upstream deletion of *LMNB*1. (C) The genomic regions of duplication (blue) and deletion (red) were analyzed using an Affymetrix CytoScan HD array and are shown on the basis of information obtained from the UCSC genome browser (assembly GRCh37/hg19). The regions of duplication were 153 kb in pedigree I, 220 kb in pedigree II, and 221 kb in pedigree III. The deletion upstream of *LMNB1* in a previous report is shown by a dotted line.^[@R8]^ The positions of original enhancer A (Enh-A) and alternative enhancer B (Enh-B) for *LMNB1* are indicated by arrowheads. ALDH7A1 = aldehyde dehydrogenase 7 family member A1; CNV = copy number variation; GRAMD3 = GRAM domain containing 3; LMNB1 = lamin B1; PHAX = phosphorylated adaptor for RNA export.](NG2018008144FF1){#F1}

Next, we determined the genomic region of the duplication by microarray-based copy number profiling using an Affymetrix CytoScan HD array. Consistent with the results of quantitative real-time PCR assay, the gene dosage of the entire region of *LMNB1* was increased ([figure 1C](#F1){ref-type="fig"}). In addition to *LMNB1*, the gene dosage of the partial region of *MARCH3* was also increased. The regions of duplication were 153 kb (hg19 chr5: 126,086,500--126,239,452) in pedigree I, 220 kb (126,012,578--126,232,143) in pedigree II, and 221 kb (126,012,161--126,233,043) in pedigree III.

Deletion upstream of *LMNB1* {#s2-2}
----------------------------

A previous study showed a 660-kb deletion upstream of *LMNB1* as a plausible cause of ADLD in an Italian family.^[@R8]^ Thus, we examined the CNV of *GRAMD3*, *ALDH7A1*, and *PHAX*, which are located upstream of *LMNB1* in 93 patients. By this analysis, we identified the deletion upstream of *LMNB1* in 2 patients in pedigree IV ([figure 1B](#F1){ref-type="fig"}). The range of deletion was determined to be 249 kb (hg19 chr5: 125,855,011-126,103,996), which includes *PHAX* and *ALDH7A1* ([figure 1C](#F1){ref-type="fig"}).

mRNA expression of *LMNB1* in blood of patients {#s2-3}
-----------------------------------------------

To ascertain whether duplication and deletion upstream of *LMNB1* found in this study result in alternation of mRNA expression of *LMNB1*, we performed quantitative real-time reverse transcription-PCR assay using RNA extracted from peripheral leukocytes of the patients. We analyzed 2 amplicons detecting the *LMNB1* transcript using 2 control transcripts of *ACTB* and *TBP*. The relative expression levels of *LMNB1* mRNA in 4 patients with *LMNB1* duplication were significantly increased in comparison with those of controls ([figure 2](#F2){ref-type="fig"}). The *LMNB1* mRNA expression level in the blood of patient 5 with the deletion was comparable to those of control subjects and his unaffected mother (data not shown).

![*LMNB1* mRNA expression\
The relative mRNA expression level of *LMNB1* in patients with *LMNB1* duplication (n = 4) and control subjects (n = 7) was determined using RNA extracted from peripheral blood by quantitative RT-PCR assay. qRT-PCR was performed using primer pairs spanning exons 6 and 7 (A and B) or exons 9 and 10 (C and D) of *LMNB1*. mRNA expression level of *LMNB1* was normalized to those of *ACTB* (A and C) and *TBP* (B and D). The average value of control subjects was set to 1. Error bars indicate standard deviation. The statistical significance of difference was examined by the Mann--Whitney *U* test. LMNB1 = lamin B1; RT = reverse transcription.](NG2018008144FF2){#F2}

Clinical characteristics {#s2-4}
------------------------

Details of clinical presentations of the patients with *LMNB1*-related ADLD are summarized in [table 1](#T1){ref-type="table"}. Familial occurrence was observed in 3 pedigrees (figure e-1, [links.lww.com/NXG/A126](http://links.lww.com/NXG/A126)). Patient 1 was apparently sporadic. Her father who died at the age of 71 years and mother at the age of 85 years did not develop ADLD. The mean age at onset of the patients with *LMNB1* duplication was 50.3 years, ranging from 44 to 55 years. The most frequent initial symptom was gait disturbance. Subsequently, pyramidal signs, ataxia, and autonomic symptoms such as orthostatic hypotension, dysuria, and constipation were observed in all the patients with *LMNB1* duplication. Notably, cognitive impairment was recognized in all the patients with the duplication. Reversible exacerbation with exposure to hot water bath or high fever was observed in patients 1, 2, 4, and 5.

###### 

Clinical features of patients with *LMNB1*-related ADLD

![](NG2018008144TT1)

The ages at onset in patients with the deletion upstream of *LMNB1* were 43 and 34 years. These patients showed pyramidal signs, ataxia, and prominent cognitive impairment. In contrast to the patients with duplication, patients with the deletion did not show apparent autonomic symptoms.

MRI characteristics {#s2-5}
-------------------

MR images of each patient are shown in [figure 3](#F3){ref-type="fig"} and figure e-2 ([links.lww.com/NXG/A126](http://links.lww.com/NXG/A126)). All the patients showed bilateral hyperintensities in the cerebral white matter and middle cerebellar peduncles (MCP) visualized by FLAIR ([figure 3](#F3){ref-type="fig"}). As previously described, the periventricular white matter was spared or less affected.^[@R1],[@R9]^ T1WI and FLAIR showed that the affected cerebral white matter appeared to be replaced by fluid ([figure 3](#F3){ref-type="fig"}, left and middle panels). The lesions of the cerebral and superior cerebellar peduncles were detectable by FLAIR in patient 1. Patients with the deletion showed a more widespread distribution of white matter lesions extending to the anterior temporal region than patients with the duplication ([figure 3B](#F3){ref-type="fig"}). DWI showed hyperintensity signals in the white matter and MCP, particularly in patients with the duplication ([figure 3, A and B](#F3){ref-type="fig"}, right panel). ADC values were increased or normal in affected lesions of the cerebral white matter (figure e-3).

![MRI findings in patients with ADLD with duplication and those with deletion upstream of *LMNB1*\
(A) Findings of MRI with T1WI (left panel), FLAIR (middle panel), and DWI (right panel) of patient 1 with *LMNB1* duplication at the age of 56 years. Arrows point to the MCP lesion. (B) Findings of MRI with T1WI (left panel), FLAIR (middle panel), and DWI (right panel) of patient 5 with the upstream deletion of *LMNB1* at the age of 50 years. ADLD = adult-onset demyelinating leukodystrophy; DWI = diffusion-weighted imaging; FLAIR = fluid-attenuated inversion recovery; MCP = middle cerebellar peduncle; LMNB1 = lamin B1.](NG2018008144FF3){#F3}

Discussion {#s3}
==========

We here report Japanese families with *LMNB1*-related ADLD carrying duplication or deletion upstream of *LMNB1*. The duplicated genomic regions in these Japanese patients were different from those of the reported families with duplication including the Japanese K4975 family.^[@R4],[@R7],[@R10]^ The genomic regions of duplication in pedigrees II and III were similar, suggesting that they may share a common founder of the duplication. We showed that the *LMNB1* mRNA expression level was significantly elevated, as determined by the analysis using RNA extracted from peripheral blood leukocytes from the patients with *LMNB1* duplication ([figure 2](#F2){ref-type="fig"}). Consistent with our results, previous reports have shown that the levels of lamin B1 protein were increased in leukocytes or brains of patients with *LMNB1* duplication.^[@R4],[@R7],[@R9],[@R11],[@R12]^ Thus, lamin B1 overproduction seems to be a key mechanism underlying the pathogenesis of ADLD. However, the pathomechanism by which *LMNB1* mRNA overexpression causes ADLD has not been fully elucidated.

Lamin B1 is a component of nuclear lamina and ubiquitously expressed in all cells with nuclei. Lamin B1 plays a role in regulating gene expression during DNA replication.^[@R13]^ It has been demonstrated that transgenic mice overexpressing *LMNB1* showed age-dependent demyelination similar to ADLD.^[@R14],[@R15]^ Comprehensive mRNA expression analysis in these mice revealed decreased mRNA expression levels of genes involved in the synthesis of lipid and cholesterol, which are the major components of myelin.^[@R14]^ This suggests that maintenance and repair of myelin may be impaired by lamin B1 overproduction, leading to the development of ADLD.

Previous studies have shown that autonomic symptoms precede or occur together with gait disturbance and motor symptoms in patients with *LMNB1* duplication.^[@R1],[@R16][@R17][@R19]^ The most frequent initial symptom was gait disturbance in our patients with duplication. Thus, it should be noted that patients with ADLD may initially show motor symptoms. Cognitive impairment was observed in all the patients with the duplication in this study, although the frequency of cognitive impairment was reported to be 63% in patients with the duplication.^[@R2],[@R3]^

The characteristics of MR images in previous reports showed changes in the cerebral white matter and middle cerebellar peduncles, which were similarly observed in our patients with the duplication.^[@R1],[@R9]^ T1WI and FLAIR revealed the white matter degeneration, which is replaced by fluid in our patients ([figure 3](#F3){ref-type="fig"}). These findings are similarly observed in patients with vanishing white matter disease (VWMD).^[@R20]^ Patients 5 and 6 were initially suspected as having VWMD, and genetic testing of *eIF2B* was performed with negative results. Thus, differential diagnosis between ADLD and VWMD may be required in patients with such MRI findings.

We identified new patients with ADLD in pedigree IV carrying the deletion upstream of *LMNB1*. The region of the deletion in this study was 249 kb, which was narrower than that of the 660-kb deletion found in the previous Italian family ([figure 1C](#F1){ref-type="fig"}).^[@R8]^ It was demonstrated that the *LMNB1* mRNA expression level was increased in brains of patients with the deletion.^[@R8]^ The deletion in the Italian pedigree contains a putative enhancer region (Enh-A) regulating *LMNB1* expression and the insulator between *PHAX* and *ALDH7A1* ([figure 1C](#F1){ref-type="fig"}). They speculated that another upstream enhancer (Enh-B) may alternatively work and enhance *LMNB1* expression if the Enh-A and the insulator are deleted. Findings in our patients with the deletion supported this notion because the 188-kb deleted region shared by our patients and the previously reported patients commonly included the insulator and Enh-A. However, the mRNA expression level of *LMNB1* derived from peripheral leukocytes did not increase in our patient with the deletion. The reason why the mRNA expression level was not apparently altered in our patient may be explained by the difference in tissues used for mRNA examination. The alternative enhancer (Enh-B) was reported to work in a forebrain-specific manner^[@R8]^; thus, its deletion may not cause the overexpression of *LMNB1* in peripheral blood in patients. The mRNA expression level of *LMNB1* may be altered in brain tissues, especially in oligodendrocytes. It would be important to analyze the *LMNB1* mRNA expression level in brains of patients with the deletion when the autopsied brain samples become available.

In previous reports, the patients with the deletion were clinically characterized by later age at onset (age at onset: 47.2 ± 6.4 years) and the absence of autonomic symptoms at onset and cerebellar ataxia, as compared with the patients with duplication.^[@R21],[@R22]^ Similarly, our patients with the deletion also lacked autonomic symptoms. In contrast to a previous report,^[@R22]^ our patients with the deletion showed relatively severe cognitive decline and the presence of cerebellar ataxia (table e-1, [links.lww.com/NXG/A126](http://links.lww.com/NXG/A126)). Cerebellar lesions were also noticeable on MR images of our patients ([figure 3B](#F3){ref-type="fig"}). The presence of cerebellar symptoms and the cerebellar lesions revealed by MRI may be characteristic in our patients with the deletion because the Italian family lacked cerebellar symptoms and rarely exhibited cerebellar lesions on MRI.^[@R22]^ A novel MR finding of this study is that the cerebral white matter lesions extended to the anterior temporal region in patients with the deletion. The temporal white matter lesions were also observed in other white matter diseases including cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy.^[@R23],[@R24]^ ADLD should be considered as a differential diagnosis for patients exhibiting anterior temporal lobe white matter lesions on MRI.

In this study, we identified 6 patients with ADLD of 93 patients with adult-onset leukoencephalopathy of unknown etiology. There were differences in clinical and MRI features between patients with ADLD with duplication and those with deletion upstream of *LMNB1*. The characteristic clinical and imaging features in patients with *LMNB1*-related ADLD may provide the clue for efficient molecular diagnosis in patients with adult-onset leukoencephalopathies.
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:   apparent diffusion coefficient

ADLD

:   adult-onset demyelinating leukodystrophy

ALDH7A1

:   aldehyde dehydrogenase 7 family member A1

CSF1R

:   colony-stimulating factor 1 receptor

CNV

:   copy number variation

DWI

:   diffusion-weighted imaging
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:   fluid-attenuated inversion recovery
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:   lamin B1
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:   middle cerebellar peduncle
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:   phosphorylated adaptor for RNA export

RIN
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:   T1-weighted imaging

VWMD

:   vanishing white matter disease
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